Slide 1: Q3 2023 update
Q3 2023 update Corporate Presentation December 2023
Slide 2: Legal notice
Legal notice This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral present
Slide 3: Corporate Summary
Poe Captor . Therapeutics CORPORATE SUMMARY
Slide 4: Captor Therapeutics – key take-aways in Q3 2023
Captor Therapeutics – key take-aways in Q3 2023 Corporate • Announcement of the next steps in the Strategy - increase of authorised share capital PLN 56,7 M incurred for R&D • Strengthening of the scientific and business team Cash flow supported by non-dilutive • Cooperation with international advis
Slide 5: ICON Clinical Research Limited - CRO company
ICON Clinical Research Limited - CRO company Globally renowned Clinical Research Organisation (CRO) More than 30 years of experience in the implementation of clinical trials of various phases, including in the field of oncology Prepare and conduct the first phase of clinical trials of an innovative
Slide 6: The landscape of biotechnology and Captor's strategic approach
The landscape of biotechnology and Captor’s strategic approach 6
Slide 7: Targeted protein degradation: a new dawn in drug discovery
TARGETED A NEW DAWN IN DRUG DISCOVERY PROTEIN The pharmaceutical market to reach $974 billion by 2030* DEGRADATION DEGRADER simultaneously bind to the bind exclusively to target protein and an E3 ubiquitin ligase, ubiquitin ligase, promoting altering its surface and BIFUNCTIONAL MOLECULAR DEGRADERS
Slide 8: Situation in US biotechnology
Situation in US biotechnology Challenging situation in US with a perspective to improve in H2 2024 • Q1 2021 – vaccine rollout to the general population; generalist investors exit biotech • Q1 2022 – first Fed funds rate increase since December 2018 – Global rate concerns dampen investor sentiment t
Slide 9: Situation in TPD space
Situation in TPD space Latest encouraging scientific achievements in TPD: • Arvinas - encouraging results Phase 1b Study of Vepdegestrant (An ER-Targeting Protein Degrader for Breast Cancer) in combination with Palbociclib; research in cooperation with Pfizer Inc. • Nurix completes Phase 1 Clinical
Slide 10: Situation in TPD space
Situation in TPD space Last TPD deals: • Orum Tx and BMS - $100M upfront/ up to $80M in milestones • Monte Rosa and Roche - $50M upfront/ up to $ 2.0B in milestones • Nurix and Seagen - $60M upfront/ up to $ 3.4B in milestones • Prelude Tx and AbCellera – ADC area – transaction value undisclosed 10
Slide 11: Roadmap to our strategic objectives
Roadmap to our strategic objectives Fully-owned portfolio of owned clinical and preclinical assets, while sharing development or commercial risks with partners at the optimum time for each asset. 4 active pipeline projects Optigrade™ Platform Clinical trials in patients of Further preclinical work 2
Slide 12: Development of Projects
Captor Poe Therapeutics” DEVELOPMENT OF PROJECTS
Slide 13: Fully owned pipeline
Fully owned pipeline # Target Indications Modality Discovery Preclinical* IND Filing Phase IA / IB FIH** GSPT1, CT-01 Hepatocellular carcinoma, NEK7, MG SALL4 Lung cancer, NET tumours Autoimmunity, CNS, CT-02 NEK7 MG Metabolism, Oncology CT-03 MCL-1 Liquid & solid tumours BID CT-05 PKCӨ Autoimmunity
Slide 14: CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader
CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader Lung cancer GSPT1 degradation leads to an Integrated Stress Response 400k patients and induction of apoptosis in HCC cells SALL4 is expressed in fetal liver, silenced in adults, but often re-expressed in HCC and correlates with poor prognosis NEK7 deg
Slide 15: CT-01: clinical trials in the short term
CT-01: clinical trials in the short term In vitro and in vivo pharmacology studies Drug Substance synthesis optimization and manufacture for tox MTD/DRF tox studies in rats and NHP DMPK studies Appointment of CRO to supervise clinical study GLP tox studies In-life phase -> completed Histopathology,
Slide 16: CT-02: Vast market potential for inflammasome modulators
CT-02: Vast market potential for inflammasome modulators Neuroinflammation NEK7 degradation inhibits the possibility of Allergy inflammasome formation and, consequently, the Asthma (AD, PD, MS, ALS) production of inflammatory cytokines leading to the reduction of symptoms of immune-related diseases
Slide 17: CT-02: spectacular results for two different strategies
CT-02: spectacular results for two different strategies Two series of potent NEK7 degraders - in autoimmune diseases (CPT-513) and neurodegenerative disorders (CPT-101, brain-penetrant series) Activity confirmed both in vitro on mouse, monkey and human cells and in vivo on mice and monkeys Specifici
Slide 18: CT-03: MCL-1 – a critical pathway of cancer resistance
CT-03: MCL-1 – a critical pathway of cancer resistance MCL-1 is one of the most amplified proteins in cancer A critical resistance mechanism in haematological and solid tumours Degradation of inhibition of MCL-1 protein directly attenuates tumours in vivo as monotherapy & sensitizes tumors for other
Slide 19: Milestones
Milestones Two bifunctional MCL-1 degraders with very high potency Selective degradation of MCL-1 and cytotoxicity in cancer cell lines in vitro & in vivo Potential inhibition of tumor growth in AML xenograft models Drug Substance production for MTD/DRF and GLP-tox Cardiosafety confirmed in vivo in
Slide 20: Optigrade discovery platform – importance of structure & chemistry
OptigradeTM discovery platform – importance of structure & chemistry OptigradeTM – addressing Molecular Glues, Bifunctional Degraders and novel Ubiquitin E3 Ligases Leading chemistry expertise in creating “activated” degraders to increase intracellular potency 20 Business Use Only | Do not use witho
Slide 21: Optigrade discovery platform
OptigradeTM discovery platform Molecular New E3 Glue CT-09 Ligases • First-in-class degrader of an Intrinsically Disordered Protein (IDP) • Demonstrated first degradation of a target protein using the novel ligase KLHDC2 • High commercial potential in CRC, hematological cancers and immuno-oncology •
Slide 22: Financials and plans for the future
FINANCIALS AND PLANS FOR THE FUTURE 22
Slide 23: Strong balance sheet and cash position
Strong balance sheet and cash position Consolidated statement of financial position (PLN, M) Cash position Available funding secured (PLN M; as of September 30, 2023): 101,3 96,3 Total : - PLN 114,3 M* PLN 54,3 cash, short-term bonds 63,5 114,3* 54,3 60,0 PLN 60,0 40,8 available grants (NCBR; ABM) 3
Slide 24: Next steps
Next steps • CT-01 • Submission of Clinical Trial Authorisation application • First patient treated • CT-03 • Candidate selection • Submission of Clinical Trial Authorisation application • CT-02 • In vivo proof of concept • Initiation of commercialisation • First degrade of a new target based on nov
Slide 25: Q&A Session
Poe Captor . Therapeutics Q&A SESSION
Slide 26: Captor Therapeutics S.A., Wrocław, Poland
Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Poland Captor Therapeutics GmbH Hegenheimermattweg 167A 4123 Allschwil, Switzerland Contact: relacje.inwestorskie@captortherapeutics.com
Slide 27: Projects co-financed by the European Regional Development Fund
Projects co-financed by the European Regional Development Fund: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor (POIR.01.01.01-00-0740/19-00) Discove